Strategic Acquisition Following its acquisition by Nexelis in 2020, AIT Bioscience has expanded its bioanalytical capabilities and integrated into a larger network, presenting opportunities to offer advanced testing platforms and tailor-made solutions to biotech and pharma clients seeking comprehensive bioanalytical services.

Sustainability & Compliance Nexelis’ investments in GCLP-certified bioanalytical laboratories highlight a focus on quality and regulatory compliance, providing a selling point for clients requiring GxP and GCLP standards, especially in clinical trial servicing and regulatory submissions.

Focused Service Expansion AIT Bioscience’s specialized bioanalytical platforms such as LC/MS and ligand binding assays enable targeted outreach to pharmaceutical companies advancing small and large molecule therapeutics—offering potential for partnerships in cutting-edge drug development projects.

Funding & Growth Potential With a revenue range of 10 to 25 million dollars and recent investments, AIT Bioscience shows growth potential which can be leveraged to position premium services in niche bioanalytical testing markets, especially among mid-sized biotech firms.

Industry Positioning As part of Nexelis, a company with a strong presence in clinical bioanalytical testing and acquisitions of GSK assets, AIT Bioscience is well-positioned to serve large pharmaceutical and contract research organizations, opening avenues for service expansion and long-term collaborations.